Squarepoint
BBNX

Squarepoint’s Beta Bionics BBNX Stock Holding History

Squarepoint’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.52M Buy
+161,098
New +$1.92M ﹤0.01% 2162
2026
Q1 		– Sell
-83,421
Closed -$2.54M – 5136
2025
Q4 		$2.54M Buy
+83,421
New +$2.23M ﹤0.01% 1894
2025
Q2 		– Sell
-11,976
Closed -$147K – 5203
2025
Q1 		$147K Buy
+11,976
New +$223K ﹤0.01% 4114

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Squarepoint's BBNX Position: Q2 2026 in Review

Squarepoint opened a new position in Beta Bionics (BBNX) in Q2 2026: 161,098 shares worth $2.52M. The stake represents ﹤0.01% of the portfolio and ranks #2162 among its holdings. This is a return to the name: Squarepoint previously reported a position in BBNX as recently as Q4 2025.

Squarepoint first reported a position in BBNX in Q1 2025 and has held it in 3 quarters since. The position peaked at $2.54M in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Squarepoint held 161,098 shares of Beta Bionics worth $2.52M as of Q2 2026.
  • Beta Bionics was a new Squarepoint position in Q2 2026.
  • Beta Bionics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2162 holding.
  • Squarepoint first reported a position in Beta Bionics in Q1 2025 and has held it in 3 quarters since.
  • Squarepoint's Beta Bionics position peaked at $2.54M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.